Search research articles
Contact Us
Filters
Showing results (121-130 of 161) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
Clinical Pharmacology and Therapeutics
|
August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Cancer Chemotherapy and Pharmacology
|
March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Enriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
David Jamieson, Melanie J Griffin, Julieann Sludden, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
BMJ Open
|
March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol
Benjamin A Fisher, Anna Rowe, Chris Hodson, et al.
Cell Reports. Medicine
|
February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
James Larkin, Richard Marais, Nuria Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 161) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Reply to E. Hindié and K.R. Hess
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, et al.
Clinical Pharmacology and Therapeutics
|
August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Cancer Chemotherapy and Pharmacology
|
March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Enriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
David Jamieson, Melanie J Griffin, Julieann Sludden, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
BMJ Open
|
March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol
Benjamin A Fisher, Anna Rowe, Chris Hodson, et al.
Cell Reports. Medicine
|
February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
James Larkin, Richard Marais, Nuria Porta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Page
of 17